C. Phillips

发表

Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenases in human and rat ocular tissues.

C. O'brien, J. Seckl, R. Andrew, 2000, Investigative ophthalmology & visual science.

Pharmacological Characterization of AZD5069, a Slowly Reversible CXCR2 Antagonist.

Alasdair, D. Nicholls, K. Wiley, 2015 .

Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.

R. Austin, D. Nicholls, A. Cook, 2015, Bioorganic & medicinal chemistry letters.

Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist

D. Nicholls, K. Wiley, I. Dainty, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition

O. Sansom, S. Woodcock, D. Flanagan, 2022, Pharmacology & therapeutics.

REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK

Victoria M Wright, Valentina Abet, J. Emmerich, 2016 .

A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.

J. Graham, S. Kopetz, J. Bridgewater, 2022, Journal of Clinical Oncology.

Lead optimisation of pyrazoles as novel FPR1 antagonists.

M. Wenlock, Bryan E. Roberts, Tony R Cook, 2012, Bioorganic & medicinal chemistry letters.

The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models

S. Woodcock, I. Bhamra, R. Armer, 2022, Cancer research communications.

Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs

Eithne Costello, S. Brumskill, L. Barrera, 2021, Journal of Physiology and Biochemistry.

Preclinical data using a novel porcupine inhibitor demonstrates that inhibition of porcupine is a promising target for the treatment of Idiopathic Pulmonary Fibrosis

I. Bhamra, R. Armer, K. Eckersley, 2019, Mechanisms of lung injury and repair.

Pharmacological Characterization of AZD 5069 , a Slowly Reversible CXC Chemokine Receptor 2 Antagonist s

D. Nicholls, K. Wiley, I. Dainty, 2015 .